COORDINATE- Diabetes, Duke Clinical Research Institute: Coordinating cardiology clinics randomized trial of interventions to improve outcomes.

Clear Outcomes, Esperion Therapeutics: The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

GUARD-AF (Device Study) – reducinG Stroke by Screening for UndiAgnosed atRial Fibrillation in Elderly individuals. 

Prominent Study, Kowa Research Institute, Inc.: The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of nonfatal Myocardial Infarction (MI), nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization; or Cardio Vascular (CV) death.

The DIAMOND trial, Relypsa, Inc: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure.

The Dal-GenE Trial, DalCor Pharmaceuticals: A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

The FINEARTS-HF Trial – A multicenter, randomized, double-blind, parallel-group, placebo-controleld study to evaluate the efficacy and safety of finerenone or morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction > 40% (LVEF >40%)